Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
ATryn developer reports Q2 net loss of $7.1 million
September 14th, 2005
GTC Biotherapeutics, Inc., (GTCB) reported its financial results for the second quarter ended July 3, 2005. The total net loss for the current quarter was $7.1 million, or $0.15 per share compared with $6.3 million, or $0.16 per share, in the second quarter of 2004. The total net loss for the first 6 months of 2005 was $15.2 million, or $0.33 per share, compared to $14.8 million, or $0.41 per share for the first 6 months of 2004. Cash and marketable securities at July 3, 2005, totaled $19.6 million compared to $22.3 million at January 2, 2005. Exclusive of the registered direct placement of common stock in January 2005, which raised $9.7 million net of placement...
Source: Vaccine Weekly (2005-09-14)
|
